At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 287 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
PF-04965842 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 CO-ADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
In Brief
A Phase 3 clinical trial evaluating Placebo, PF-04965842, and 1 other intervention for Atopic Dermatitis. Completed, enrolled 287 participants across 136 sites in 14 countries.
Detailed Summary
This is a randomized, double blind, placebo controlled, parallel group, Phase 3 study to evaluate the efficacy and safety of PF 04965842 in adolescent participants 12 to \<18 years of age with moderate to severe AD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesAustralia, China, Czechia, Germany, Hungary, Italy, Japan, Latvia, Mexico, Poland, Spain, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedJan 2019
Enrollment StartFeb 2019
Primary CompletionApr 2020
TodayJul 2026
First PostedJan 8, 2019
Enrollment StartFeb 18, 2019
Primary CompletionApr 8, 2020
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 7.5 years ago
Interventions
Placebodrug
Placebo
PF-04965842drug
100 mg QD
PF04965842drug
200 mg QD